Clearstead Advisors’s Krystal Biotech KRYS Stock Holding History

Clearstead Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.09K	Buy	+11	New	+$3.29K	﹤0.01%	2250
2026 Q1	–	Sell	-28	Closed	-$6.9K	–	2581
2025 Q4	$6.9K	Sell	28 -5	-15%	-$1.05K	﹤0.01%	1961
2025 Q3	$5.83K	Buy	33 +9	+38%	+$1.35K	﹤0.01%	2099
2025 Q2	$3.3K	Hold	24	–	–	﹤0.01%	2217
2025 Q1	$4.33K	Hold	24	–	–	﹤0.01%	1775
2024 Q4	$3.76K	Sell	24 -15	-38%	-$2.66K	﹤0.01%	1767
2024 Q3	$7.1K	Buy	+39	New	+$7.52K	﹤0.01%	1653

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Clearstead Advisors's KRYS Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Krystal Biotech (KRYS) in Q2 2026: 11 shares worth $4.09K. The stake represents ﹤0.01% of the portfolio and ranks #2250 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in KRYS as recently as Q4 2025.

Clearstead Advisors first reported a position in KRYS in Q3 2024 and has held it in 7 quarters since. The position peaked at $7.1K in Q3 2024. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Clearstead Advisors held 11 shares of Krystal Biotech worth $4.09K as of Q2 2026.
Krystal Biotech was a new Clearstead Advisors position in Q2 2026.
Krystal Biotech made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2250 holding.
Clearstead Advisors first reported a position in Krystal Biotech in Q3 2024 and has held it in 7 quarters since.
Clearstead Advisors's Krystal Biotech position peaked at $7.1K in Q3 2024.
424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.